Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Radioresistance of non-small cell lung cancer cells

PROVIDER: PRJNA732559 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR14639137_1.fastq.gz	Fastqsanger.gz
	SRR14639137_2.fastq.gz	Fastqsanger.gz
	SRR14639138_1.fastq.gz	Fastqsanger.gz
	SRR14639138_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 4 of 4

Similar Datasets

Next Generation Sequencing of H292 cell line cultured with CAFs CM or SL-CAFs CM

Project description:Cancer cell radioresistance is the primary cause of the decreased curability of non-small cell lung cancer (NSCLC) observed in patients receiving definitive radiotherapy (RT). Following RT, a set of microenvironmental stress responses is triggered, including cell senescence. However, cell senescence is often ignored in designing effective strategies to resolve cancer cell radioresistance. Herein, we identified the senescence-like characteristics of cancer-associated fibroblasts (CAFs) post RT and clarified the formidable ability of senescence-like CAFs in promoting NSCLC cells proliferation and radioresistance through the JAK/STAT pathway. Specific induction of senescence-like CAFs apoptosis using FOXO4-DRI, a FOXO4-p53 interfering peptide, resulted in remarkable effects on radiosensitizing NSCLC cells in vitro and in vivo. In addition, our study also discovered the obvious therapeutic effect of FOXO4-DRI on alleviating radiation-induced pulmonary fibrosis (RIPF) by targeting senescence-like fibroblasts in vivo. In conclusion, by targeting senescence, we offer a new strategy which simultaneously decreases radioresistance of NSCLC and the incidence of RIPF.

2021-10-15 | GSE185698 | GEO

Homo sapiens

Project description:Non Small Cell Lung Cancer

| PRJNA90997 | ENA

CDK5 activates Hippo signaling to confer resistance to radiotherapy via upregulating TAZ in lung cancer

Project description:Tumor resistance to radiotherapy is a therapeutic challenge in the treatment of patients with lung cancer. Cyclin-dependent kinase 5 (CDK5) has been proposed to participate in cell proliferation, migration and invasion; drug resistance; and immune evasion. However, the functions and regulatory mechanisms of CDK5 in lung cancer radioresistance have not been investigated.SiRNAs and ShRNAs were used to knock down CDK5 in A549 and H1299 cells. The effects of CDK5 depletion on the tumorigenic behaviors of non-small cell lung cancer (NSCLC) cells were evaluated in vitro and in vivo. Gene expression was examined by RNA-seq and quantitative real-time PCR.

2021-04-30 | GSE148532 | GEO

Targeted proteomic analysis of small GTPases in radioresistant breast cancer cells

Project description:Radiotherapy benefits more than 50% of cancer patients and cures 40% of them, where ionizing radiation deposits energy to cells and tissues, thereby eliciting DNA damage and resulting in cell death. Small GTPases are a superfamily of proteins that play critical roles in cell signaling. Several small GTPases, including RAC1, RHOB and RALA, were previously shown to modulate radioresistance in cancer cells. However, there is no systematic proteomic study on small GTPases that regulate radioresistance in cancer cells. Herein, we applied a high-throughput scheduled multiple-reaction monitoring (MRM) method, along with the use of synthetic stable isotope-labeled peptides, to identify differentially expressed small GTPase proteins in two pairs of breast cancer cell lines, MDA-MB-231 and MCF7, and their corresponding radioresistant lines. We identified 7 commonly altered small GTPase proteins with over 1.5-fold change in the two pairs of cell lines. We also discovered ARFRP1 as a novel radioresistance regulator, where its downregulation promotes radioresistance in breast cancer cells. Together, this represents the first comprehensive assessment about the differential expression of the small GTPase proteome associated with the development of radioresistance in breast cancer cells. Our work also uncovered ARFRP1 as a new target for enhancing radiation sensitivity in breast cancer.

2024-01-26 | PXD034360 | Pride

Identification of Key Gene and Functional Pathways in Radioresistance of non-small cell lung cancer

Project description:Identification of Key Gene and Functional Pathways in Radioresistance of non-small cell lung cancer

| PRJNA809408 | ENA

Project description:Lung microbiome of non-small cell lung cancer

| PRJNA647170 | ENA

Project description:Lung microbiome in non-small cell lung cancer

| PRJNA773392 | ENA

USP9X-mediated KDM4C deubiquitination promotes lung cancer radioresistance by epigenetically inducing TGFβ2 transcription

Project description:Radioresistance is regarded as the main barrier to effective radiotherapy in lung cancer. However, the underlying mechanisms of radioresistance remain elusive. Here, we show that lysine-specific demethylase 4C (KDM4C) is overexpressed and correlated with poor prognosis in lung cancer patients. We provide evidence that genetical or pharmacological inhibition of KDM4C impairs tumorigenesis and radioresistance in lung cancer in vitro and in vivo. Moreover, we uncover that KDM4C upregulates TGFβ2 expression by directly reducing H3K9me3 level at the TGFβ2 promoter and then activates TGF-β/Smad/ATM signaling to confer radioresistance in lung cancer. Using tandem affinity purification technology, we further identify deubiquitinase USP9X as a critical binding partner which deubiquitinates and stabilizes KDM4C. More importantly, depletion of USP9X impairs TGF-β/Smad signaling and radioresistance by destabilizing KDM4C in lung cancer cells. Thus, our findings demonstrate that USP9X-mediated KDM4C deubiquitination activates TGF-β/Smad signaling to promote radioresistance, suggesting that targeting KDM4C may be a promising radiosensitization strategy in the treatment of lung cancer.

2021-07-14 | GSE136404 | GEO

Project description:Non-small Cell Lung Cancer (qRT-PCR)

| PRJNA107251 | ENA

Postoperative circulating tumor DNA monitoring for stage I-III non-small cell lung cancer

Project description:The target sequecing vcf data of tumor and curculating tumor DNA for non-small cell lung cancer patients.

2022-05-09 | PRJEB52694 | EVA